GENOVIS: COMMUNIQUÉ FROM ANNUAL GENERAL MEETING FOR GENOVIS AB (PUBL) June 9, 2011

The following decisions were adopted at the Annual General Meeting:

The balance sheet and income statement were ratified.

The Board of Directors and the CEO were discharged from liability.

The Board shall consist of six ordinary members with no alternates until the next Annual General Meeting.

Nicklas Gerhardsson, Thomas Laurell and Carina Schmidt, Fredrik Lindgren and Ebba Åsly Fåhraeus were re-elected as Board members. Jacob Engellau was elected new Board member since

Hans Göran Arlock has declined re-election. Ebba Åsly Fåhraeus was elected as Chairman of the Board.

A Nominating Committee shall be formed by 30 September 2011, and consist of representatives for the four biggest shareholders at the time, provided these shareholders are not Board members.

Guidelines for remuneration for the CEO and other leading employees were ratified in accordance with the Board’s proposal.

The Annual General Meeting resolved to change sections 4 and 5 of the Articles of Association concerning share capital and number of shares. The share capital shall comprise at the lowest

sixteen million four hundred thousand (16.400.000) SEK and at the highest sixty-five million six hundred thousand (65.600.000) SEK.

The number of shares shall be at the lowest forty-one million (41.000.000) and at the highest one hundred sixty-four million (164.000.000).

The AGM decided to grant authorization to the Board, for a period that does not extend past the date of the next Annual General Meeting, on one or several occasions, with or without pre-emptive rights for shareholders, to resolve on the issue of new shares, convertibles or subscription options. It should also be possible to make such an issue resolution stipulating cash payment and / or stipulating payment in kind or set-off or otherwise with conditions. The issue price for the new shares shall, in each instance, be set as close as possible to the market price of the Company’s share.

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 46 10 12 35 sarah.fredriksson@genovis.com

Genovis develops and designs smart nanoparticles for preclinical imaging and diagnostics and also develops and sells tools for modification of antibodies.Genovis shares are listed on Nasdaq OMX First North and Thenberg & Kinde Fondkommission ( 46 (0)31 745 50 00) is the Company’s certified adviser.